Pipeline

Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1

73%

Ulcerative Colitis (UC) 2

73%

Crohn’s Disease (CD)

73%

Primary Biliary Cholangitis

56%

Atopic Dermatitis (AD)

45%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Olorinab
Highly Selective Full Agonist CB2
Pain Associated with IBD

60%

Pain Associated with IBS

45%

Arena: Worldwide
Ralinepag
Potent IP Receptor Agonist
PAH – Time to Clinical Events

73%

PAH – Exercise Capacity (6MWD)

73%

PAH – Exercise Capacity (CPET)

73%

PAH – Differentiation

42%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
APD418
Calcium-Independent Myofilament Derepressor
Decompensated heart failure (DHF)

17%

Arena: Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing

98%

Eisai: Worldwide
Nelotanserin
5-HT2A Inverse Agonist
REM Sleep Behavior Disorder in Dementia with Lewy Bodies

41%

Axovant: Worldwide
Undisclosed Orphan GPCR
CNS

15%

Undisclosed Orphan GPCR
Undisclosed Novel GPCR
Genitourinary Disorders

15%

Outpost Medicine

Program Indication Phase
Internal Programs
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1 Ph3 Planning
Ulcerative Colitis (UC) 2 Ph3 Planning
Crohn’s Disease (CD) Ph2/3 Planning
Primary Biliary Cholangitis Ph2 2H:19
Atopic Dermatitis (AD) Ph2 Planning
Olorinab
Highly Selective Full Agonist CB2
Pain Associated with IBD Ph2 Data
Pain Associated with IBS Ph2 Planning
Ralinepag
Potent IP Receptor Agonist
PAH – Time to Clinical Events Ph3 Initiated
PAH – Exercise Capacity (CPET) Ph3
PAH – Exercise Capacity (6MW) Ph3
PAH – Differentiation 1H:19 Initiation
APD418
Calcium-Independent Myofilament Derepressor
Decompensated heart failure (DHF) IND 2019
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing Post Market
Nelotanserin
5-HT2A Inverse Agonist
REM Sleep Behavior Disorder in Dementia with Lewy Bodies Ph2
Undisclosed Orphan GPCR
CNS PC
Undisclosed Novel GPCR
Genitourinary Disorders PC

Expanded Access Policy